PE20011120A1 - Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad - Google Patents

Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad

Info

Publication number
PE20011120A1
PE20011120A1 PE2001000014A PE2001000014A PE20011120A1 PE 20011120 A1 PE20011120 A1 PE 20011120A1 PE 2001000014 A PE2001000014 A PE 2001000014A PE 2001000014 A PE2001000014 A PE 2001000014A PE 20011120 A1 PE20011120 A1 PE 20011120A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
antagonists
pharmaceutical compositions
cardiovascular morbidity
Prior art date
Application number
PE2001000014A
Other languages
English (en)
Inventor
Wesley Warren Day
David Duane Thompson
Andrew George Lee
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011120A1 publication Critical patent/PE20011120A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE UN COMPUESTO DE FORMULA I; DONDE A ES CH2, NR; B, D Y E SON CH, N; Y ES FENILO, NAFTILO, CICLOALQUILO C3-C8, HETEROCICLO; Z1 ES -(CH2)pW(CH2)q, -O(CH2)pCR5R6, -O(CH2)pW(CH2)q, ENTRE OTROS; G ES NR7R8, GRUPO a; DONDE n ES 0-2, m ES 1-3; W ES CH2, CH=CH, O, NR2, S(O)n, ENTRE OTROS; R ES H, ALQUILO C1-C6, R2 Y R3 SON H, ALQUILO C1-C4,; R4 ES H, HALO, ALQUILO C1-C6, ALCOXI C1-C4, ALQUIL(C1-C4)TIO; ALQUIL(C1-C4)SULFINILO, ENTRE OTROS; R5 Y R6 SON ALQUILO C1-C8 O JUNTOS FORMAN UN CARBOCICLO C3-C10; R7 Y R8 SON FENILO, CARBOCICLO C3-C10, HETEROCICLO C3-C10, H, ALQUILO C1-C6, ENTRE OTROS; e ES 0-2, p ES 0-3, q ES 0-3. SON COMPUESTOS PREFERIDOS CIS-6-(4-FLUOROFENIL)-5-[4-(2-PIPERIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRO-NAFTALEN-2-OL, (-)-CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRO-NAFTALEN--2-OL, ENTRE OTROS. EL COMPUESTO I ES UN AGONISTA/ANTAGONISTA DE ESTROGENOS Y REDUCE EL RIESGO DE MORBILIDAD Y/O MORTALIDAD CARDIOVASCULAR, CANCER DE MAMA, OSTEOPOROSIS
PE2001000014A 2000-01-12 2001-01-08 Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad PE20011120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17566300P 2000-01-12 2000-01-12

Publications (1)

Publication Number Publication Date
PE20011120A1 true PE20011120A1 (es) 2001-11-05

Family

ID=22641136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000014A PE20011120A1 (es) 2000-01-12 2001-01-08 Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad

Country Status (11)

Country Link
US (1) US20010056099A1 (es)
EP (1) EP1118323A3 (es)
JP (1) JP2001226265A (es)
KR (1) KR100402562B1 (es)
AU (1) AU1113101A (es)
CA (1) CA2331059A1 (es)
CO (1) CO5271696A1 (es)
HU (1) HUP0100119A3 (es)
IL (1) IL140801A0 (es)
PE (1) PE20011120A1 (es)
ZA (1) ZA200100276B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296674A2 (en) * 2000-07-06 2003-04-02 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US7295691B2 (en) * 2002-05-15 2007-11-13 Ge Medical Systems Global Technology Company, Llc Computer aided diagnosis of an image set
JP2005060303A (ja) * 2003-08-12 2005-03-10 Sutaagen:Kk 不動性骨粗鬆の治療または予防剤
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN101022802A (zh) 2004-07-22 2007-08-22 Ptc医疗公司 用于治疗丙型肝炎的噻吩并吡啶化合物
MX2012014431A (es) 2010-06-10 2013-02-26 Aragon Pharmaceuticals Inc Modulares del receptor de estrogenos y usos de los mismos.
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
AU2016331065B2 (en) 2015-10-01 2021-04-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs
EP3386968A4 (en) 2015-12-09 2019-09-25 The Board of Trustees of the University of Illinois BENZOTHIOPHEN-BASED SELECTIVE ESTROGEN RECEPTOR-DOWN-REGULATING PREPARATIONS
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EA201990187A1 (ru) 2016-07-01 2019-07-31 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
BR112019013814A2 (pt) 2017-01-06 2020-01-21 G1 Therapeutics Inc método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
AU2018217809A1 (en) 2017-02-10 2019-08-22 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
AU2018291026B2 (en) 2017-06-29 2022-09-01 G1 Therapeutics, Inc. Morphic forms of GIT38 and methods of manufacture thereof
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
JP2023509375A (ja) 2019-12-20 2023-03-08 シーフォー セラピューティクス， インコーポレイテッド Ｅｇｆｒの分解のためのイソインドリノン及びインダゾール化合物
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція

Also Published As

Publication number Publication date
IL140801A0 (en) 2002-02-10
ZA200100276B (en) 2002-07-10
CO5271696A1 (es) 2003-04-30
EP1118323A3 (en) 2003-05-21
EP1118323A2 (en) 2001-07-25
US20010056099A1 (en) 2001-12-27
CA2331059A1 (en) 2001-07-12
HU0100119D0 (en) 2001-03-28
KR20010083102A (ko) 2001-08-31
KR100402562B1 (ko) 2003-10-17
HUP0100119A2 (en) 2002-10-28
JP2001226265A (ja) 2001-08-21
HUP0100119A3 (en) 2004-04-28
AU1113101A (en) 2001-07-19

Similar Documents

Publication Publication Date Title
PE20011120A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad
PE20011046A1 (es) Composiciones y procedimientos para el tratamiento de afecciones que responden a estrogenos
PE20011294A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
EA200201141A1 (ru) Производные тропана, полезные для терапии
EA200200770A1 (ru) Производные пурина
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
DE60107449D1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
CY1109915T1 (el) Φαρμακευτικες συνθεσεις οιστρογονων μεσων
AR028952A1 (es) Antagonistas receptores de trombina
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
CY1107221T1 (el) Παραγωγα τριαζολιου ως ανταγωνιστες υποδοχεα ταχυκινινης
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
CO5630034A2 (es) Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
EA199800912A1 (ru) Дигидратная соль мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2(1н)-индол-2-она, фармацевтическая композиция и способ лечения психотического расстройства
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
AR017864A1 (es) Compuestos de 1-[aril o heteroaril]-4-[3-fenil, naftil o cicloalquil-metilen, carbonil o hidroximetil]-3-[fenil-propil]piperazina, que poseen actividadsobre los receptores 1a de la serotonina, composiciones farmaceuticas formuladas con dichos compuestos; compuestos intermediarios para la sintesisde

Legal Events

Date Code Title Description
FC Refusal